Premium
Acetazolamide Toxicity and Pharmacokinetics in Patients Receiving Hemodialysis
Author(s) -
Schwenk Michael H.,
Peter Wendy L. St.,
Meese Martin G.,
Singhal Pravin C.
Publication year - 1995
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1995.tb04392.x
Subject(s) - acetazolamide , toxicity , lethargy , medicine , hemodialysis , pharmacokinetics , anesthesia , dialysis , pharmacology
Acetazolamide‐induced central nervous system toxicity occurred in two patients undergoing hemodialysis. Symptoms of toxicity included fatigue, lethargy, and confusion, which resolved several days after discontinuing acetazolamide. Pharmacokinetic studies showed markedly elevated serum concentrations of the drug during the period of toxicity, which decreased at a slower rate compared with that reported in patients with normal renal function. The effect of hemodialysis on acetazolamide clearance was quantified. The agent should be avoided in patients receiving dialysis unless the dosage is reduced and serum concentration monitoring can be performed in a timely manner. These patients should be monitored closely for central nervous system toxicity if acetazolamide is given.